GlassScriptPhysician profile
Darryle P Bullard
NPI 1245288653
$30,036.17
in general payments reported to CMS, 2019-2025
42 companies · $24K in 2025
The $24K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.56 · 2021: $1,189 · 2022: $1,843 · 2023: $1,644 · 2024: $1,760 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $19K · Food and Beverage: $5,861 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,266 · Education: $556 · Travel and Lodging: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $18,800.00 |
| Food and Beverage | $5,861.34 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,266.23 |
| Education | $556.27 |
| Travel and Lodging | $503.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $21,558.79 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $2,025.75 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,812.19 | 2021-2025 | Airsupra, Tezspire, Breztri |
| Insmed, INC. | $461.92 | 2021-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $435.20 | 2021-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.91 | 2020-2025 | Ofev, Jascayd |
| Baxter Healthcare | $359.25 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Mallinckrodt Hospital Products INC. | $327.97 | 2021-2025 | Acthar |
| Mylan Specialty L.P. | $311.02 | 2021-2024 | Yupelri |
| Philips North America LLC | $277.97 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Genzyme Corporation | $277.34 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.54 | 2021-2025 | Glassia |
| Axsome Therapeutics, INC. | $162.06 | 2024-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $134.95 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $130.38 | 2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $114.54 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $113.46 | 2022-2024 | Opdivo, Opdualag |
| Amgen INC. | $112.98 | 2021-2025 | Tezspire, Otezla, Enbrel |
| Ucb, INC. | $89.66 | 2022-2023 | Cimzia |
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 | |
| Viatris Specialty LLC | $82.29 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $69.30 | 2024 | |
| Neurocrine Biosciences, INC. | $62.41 | 2024 | Ingrezza |
| Lilly USA, LLC | $58.97 | 2021-2025 | Zepbound |
| Abbvie INC. | $53.05 | 2023-2024 | Botox |
| United Therapeutics Corporation | $46.04 | 2023-2024 | Tyvaso |
| Eisai INC. | $42.73 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $37.12 | 2023 | Nuzyra |
| Vapotherm INC | $34.09 | 2022 | |
| Pulmonx Corporation | $31.68 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Pacira Pharmaceuticals Incorporated | $24.98 | 2023 | Zilretta |
| Tactile Systems Technology INC | $21.72 | 2024 | Entre Plus, Flexitouch Plus |
| Neurelis, INC. | $20.77 | 2023 | Valtoco |
| Ani Pharmaceuticals, INC. | $19.40 | 2022 | |
| Sk Life Science, INC. | $18.15 | 2023 | |
| Acorda Therapeutics, INC | $16.99 | 2023 | Inbrija |
| Teva Pharmaceuticals USA, INC. | $16.58 | 2025 | Austedo Xr |
| Boston Scientific Corporation | $16.04 | 2022 | |
| Merck Sharp & Dohme LLC | $15.00 | 2021 | |
| Adlon Therapeutics L.P. | $13.74 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.25 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$700,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryle Bullard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.